Zoledronic acid inhibits growth of hepatocellular carcinoma cells in vitro and in vivo

Chinese Medical Journal

Volumn 126, Issue 8, 2013, Pages 1486-1490

  Liu, Quan ^a   Tao, Yong Hui ^b   Bai, Rui Zhen ^a   Chang, Shu Jian ^a   Hua, Dong ^a  

^a Soochow University   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

Hepatocellular carcinoma; S phase arrest; Zoledronic acid

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; PROTEIN P53; SULFORHODAMINE B; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ASCITES; CANCER SURVIVAL; CELL CYCLE CHECKPOINT; CELL CYCLE S PHASE; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; IMMUNODETECTION; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; OPTICAL DENSITY; PROTEIN CONTENT; PROTEIN EXPRESSION; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LIVER NEOPLASMS; MICE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876391551     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20122385     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
3. Shi XJ, Jin X, Wang MQ, Wei LX, Ye HY, Liang YR, et al. Effect of resection following downstaging of unresectable hepatocelluar carcinoma by transcatheter arterial chemoembolization. Chin Med J 2012; 125: 197-202.
4. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
5. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19: 420-432.
6. Di Salvatore M, Orlandi A, Bagala C, Quirino M, Cassano A, Astone A, et al. Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif 2011; 44: 139-146.
7. Koto K, Murata H, Kimura S, Horie N, Matsui T, Nishigaki Y, et al. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Oncol Rep 2010; 24: 233-239.
8. Sewing L, Steinberg F, Schmidt H, Goke R. The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 2008; 13: 782-789.
9. Matsumoto S, Kimura S, Segawa H, Kuroda J, Yuasa T, Sato K, et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 2005; 47: 31-39.
10. Lamoureux F, Ory B, Battaglia S, Pilet P, Heymann MF, Gouin F, et al. Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid. Int J Cancer 2008; 122: 751-760.
11. Wakchoure S, Merrell MA, Aldrich W, Millender-Swain T, Harris KW, Triozzi P, et al. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res 2006; 12: 2862-2868.
12. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005; 104: 2522-2529.
13. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365: 1396-1405.
14. Bradford MM, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
15. Okamoto S, Kawamura K, Li Q, Yamanaka M, Yang S, Fukamachi, et al. Zoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in p53-independent and ras prenylation-independent manners. JThorac Oncol 2012; 7: 873-882.
16. Romani AA, Desenzani S, Morganti MM, La Monica S, Borghetti AF, Soliani P. Zoledronic acid determines S-phasearrest but fails to induce apoptosis in cholangiocarcinoma cells. Biochem Pharmacol 2009; 78: 133-141.
17. Ohnuki H, Izumi K, Terada M, Saito T, Kato H, Suzuki A, etal. Zoledronic acid induces S-phase arrest via a DNA damage response in normal human oral keratinocytes. Arch Oral Biol 2012; 57: 906-917.
18. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004; 114: 623-633.
19. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004; 10: 4559-4567.
20. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002; 42: 1228-1236.
21. Gao L, Deng H, Zhao H, Hirbe A, Harding J, Ratner L, et al. HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood 2005; 106: 4294-4302.
22. Daubine F, Le Gall C, Gasser J, Green J, Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007; 99: 322-330.
23. Peng H, Sohara Y, Moats RA, Nelson MD, Jr., Groshen SG, Ye W, et al. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Cancer Res 2007; 67: 9346-9355.
24. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma Gastroenterology 2004; 127 (5 Suppl 1): S179-S188.
25. Huppert P. Current concepts in transarterial chemoembolization of hepatocellular carcinoma. Abdom Imaging 2011; 36: 677-683.
26. Fan QS, Huo XK, Wang MQ, Liu FY, Duan F, Wang ZJ, et al. Efficacy and safety of transcatheter chemoembolization of the internal thoracic artery in patients with hepatocellular carcinoma. Chin Med J 2011; 124: 1374-1380.